相关实验视频

Updated: Jan 15, 2026

Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae

Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae

Published on: February 24, 2023

[瑞士和其他国家的抗宏化物耐药Mycoplasma pneumoniae肺炎]

Vanessa Stornelli¹, Kathlyn Schreiter-Milcent², Jens Greiser¹

¹Service de médecine interne générale, Centre hospitalier du Valais romand, Hôpital de Sion, 1951 Sion.

Revue medicale suisse

|October 9, 2025

概括

耐宏化物耐药的Mycoplasma pneumoniae (MR-MP) 感染会在儿童和成年人中引起长期症状. 东环素是瑞士成年人MR-MP的推第一线治疗方法,尽管最初的症状与敏感菌株相似.

科学领域:

传染性疾病传染性疾病
微生物学微生物学
肺部病理学肺部病理学

背景情况:

肺炎神经质菌通常会引起轻度下呼吸道感染,主要发生在学龄儿童和年轻人身上.
抗宏化物耐药的Mycoplasma pneumoniae (MR-MP) 感染表现相似,但伴有长期发烧,咳和住院治疗.
延迟开始治疗是长期MR-MP症状的结果,尽管并发症并没有增加.

研究的目的:

描述Mycoplasma pneumoniae感染的临床表现和治疗方法,重点关注抗化物耐药菌株.
突出目前瑞士成年人MR-MP的第一线治疗建议.

主要方法:

对由Mycoplasma pneumoniae引起的下呼吸道感染的临床特征的审查.
对抗宏类抗菌株的临床图像和治疗结果的分析.
对瑞士对MR-MP感染的当前治疗指南的审查.

主要成果:

与宏类敏感菌株相比,MR-MP感染与症状持续时间和住院时间的延长有关.
长时间的MR-MP疗程不会增加严重并发症的风险.
在瑞士,多西环素已被确立为成人MR-MP感染的主要治疗方法.

结论:

由于长期的疾病,MR-MP需要仔细考虑,影响治疗时间表.
在瑞士,多西环素作为MR-MP在成年人群中的有效一线治疗.
进一步的研究可能会探索儿童MR-MP病例的最佳管理策略.

更多相关视频

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

相关概念视频

Pneumonia I: Introduction

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...

Pneumonia V: Nursing management and Prevention

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....

Pneumonia IV: Management

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

Pneumonia III: Complications and Assessment

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following: